Use of arbutin and edelweiss extract, inhibitors and skin care products

Abstract

The application discloses a use, an inhibitor and a skin care product of arbutin and high mountain firebrush extract, and can solve the problem of how to inhibit the expression level of the protein content of gamma H2AX. The DNA damage inhibitor comprises alpha-arbutin and high mountain firebrush extract, and the mass ratio of the alpha-arbutin and the high mountain firebrush extract is 0.5-70:1.

Description

Technical Field

[0001] This invention relates to the field of skincare technology. More specifically, this invention relates to the uses, inhibitors, and skincare products of arbutin and edelweiss extract. Background Technology

[0002] DNA double-strand breaks (DSBs) are considered the most serious form of DNA damage. After DSBs occur, cells can produce a series of stress responses, one important of which is the signaling cascade initiated by the capillary ataxia mutant gene, which can arrest the cell cycle until the damage is repaired.

[0003] H2AX is a histone that can form a complex with DNA. DSBs (damage-dependent DNA breaks) cause rapid phosphorylation of the Ser residues in H2AX, forming phosphorylated histones (called γH2AX or ganunaH2AX). Phosphorylated histones can recruit DNA damage response proteins (i.e., DNA repair proteins), playing a crucial role in subsequent DNA damage repair. Therefore, γH2AX is a marker protein for DSBs. Thus, studying the working principle of DNA through γH2AX is of great significance for understanding DNA damage repair.

[0004] Keratinocytes are the main building blocks of the epidermis, accounting for more than 80% of epidermal cells, and produce keratin during differentiation. Based on their differentiation stage and characteristics, they can be divided into five layers, from the inside out: the basal layer, the spinous layer, the granular layer, the stratum lucidum, and the stratum corneum. Keratinocytes function to form the skin barrier, protecting against environmental damage caused by heat, ultraviolet radiation, moisture loss, pathogens, fungi, parasites, and viruses. However, ultraviolet radiation causes direct DNA damage to keratinocytes.

[0005] Currently, research on DNA damage in keratinocytes caused by ultraviolet radiation is still insufficient, and there are still limited DNA repair substances that can be used to inhibit the expression level of γH2AX in keratinocytes. Summary of the Invention

[0006] One object of the embodiments of the present invention is to solve the above-mentioned problems and to provide advantages that will be described later.

[0007] As the analysis in the background section indicates, studying the repair mechanisms of damaged DNA is a crucial issue currently facing this field. There are various mechanisms for repairing damaged DNA, and among them, developing novel applications for DNA damage repair based on existing substances is a highly valuable direction. For this purpose, this application screened two widely applicable skincare ingredients—arbutin and edelweiss extract—from a large pool of existing substances and investigated their relationship with γH2AX expression levels.

[0008] Arbutin is a commonly used whitening agent that exerts its whitening effect by inhibiting tyrosinase activity. Edelweiss (Leontopodium alpinum), also known as snowdrop, has free radical scavenging and antioxidant properties, and both are frequently used in skincare product preparation. Previously, neither was considered effective in repairing DNA damage. However, this application's embodiments, through experimental verification, unexpectedly discovered that arbutin and edelweiss extract, at a specific ratio, can inhibit the relative protein expression level of γH2AX, demonstrating a significant repair effect on DNA damaged by ultraviolet irradiation. Therefore, another objective of this invention is to provide the uses, inhibitors, and skincare products of arbutin and edelweiss extract, addressing the issue of how to inhibit the protein expression level of γH2AX, thereby achieving a DNA repair effect.

[0009] The embodiments of this application mainly achieve the above objectives through the following technical solutions.

[0010] In a first aspect, embodiments of this application propose the use of arbutin in synergistic inhibition of DNA damage by Edelweiss extract.

[0011] In a second aspect, embodiments of this application propose the use of Edelweiss extract for synergistic inhibition of DNA damage with arbutin.

[0012] In a third aspect, embodiments of this application propose the use of a composition containing arbutin and edelweiss extract for repairing DNA damage.

[0013] In a fourth aspect, embodiments of this application propose the use of a composition containing arbutin and edelweiss extract in the preparation of a DNA damage inhibitor.

[0014] In a fifth aspect, embodiments of this application propose the use of a composition containing arbutin and edelweiss extract in the preparation of cosmetics or pharmaceuticals for inhibiting DNA damage.

[0015] In a sixth aspect, embodiments of this application propose a DNA damage inhibitor, comprising:

[0016] α-Arbutin;

[0017] Edelweiss extract;

[0018] The mass ratio of α-arbutin to Edelweiss extract is 0.5–70:1; preferably, it is 0.5–5:1.

[0019] In some technical solutions, the mass ratio of α-arbutin to Edelweiss extract is 1 to 5:1, and more specifically 2:1.

[0020] The sixth aspect, the DNA damage inhibitor, is a compound of α-arbutin and edelweiss extract in a specific ratio, which has a significant repair effect on DNA damage caused by UVB irradiation of keratinocytes.

[0021] In a seventh aspect, embodiments of this application provide a skincare product comprising:

[0022] The DNA damage inhibitor described in the sixth aspect of the embodiments.

[0023] In some technical solutions, the mass percentage of α-arbutin is 0.04% to 2% based on the total mass of the product; and the mass percentage of Edelweiss extract is 0.01% to 5%.

[0024] In some technical solutions, the skin care products are face creams, sunscreens, moisturizing creams, face masks, serums, eye creams, makeup bases, foundations, concealers, lotions, cleansers, toners, softening lotions, astringents, cosmetics, or body lotions, etc.

[0025] It should be noted that in some technical solutions, the Edelweiss extract described in the above embodiments can be prepared according to the preparation method shown in the following steps:

[0026] The alpine edelweiss was dried and pulverized by blowing, and then passed through a 40-60 mesh sieve to obtain alpine edelweiss powder.

[0027] The pulverized edelweiss is mixed with an aqueous ethanol solution of 60-80% by mass to obtain a mixed solution, wherein the mass-to-volume ratio of the pulverized edelweiss to the aqueous ethanol solution in the mixed solution is 1:2.5-3.5 g / ml; it should be noted that each 1 g of pulverized edelweiss corresponds to 2.5-3.5 ml of aqueous ethanol solution;

[0028] The mixed solution was refluxed at 80-90°C for 40-60 minutes, filtered through a 500-800 mesh filter cloth, and the filtrate was concentrated under reduced pressure to obtain Edelweiss extract.

[0029] The beneficial effects that can be achieved by the embodiments of this application include:

[0030] In some embodiments, the use of arbutin, edelweiss extract and their composition provided in this application can solve the problem of how to inhibit the expression level of γH2AX protein, thereby achieving the effect of DNA repair.

[0031] In some embodiments, the DNA damage inhibitor provided in this application can solve the problem of how to inhibit the expression level of the relative protein content of γH2AX, thereby achieving the effect of repairing DNA.

[0032] In some embodiments, the skincare products provided in this application can solve the problem of how to inhibit the expression level of the relative protein content of γH2AX, thereby achieving the effect of repairing DNA.

[0033] Other advantages, objectives and features of the present invention will become apparent in part from the following description, and in part from those skilled in the art through study and practice of the invention. Attached Figure Description

[0034] Figure 1 This is a schematic diagram showing the relative protein content levels of γ-H2AX in each group in the embodiments of this application;

[0035] Figure 2 This is another schematic diagram showing the relative protein content levels of γ-H2AX in each group of embodiments of this application. Detailed Implementation

[0036] The present invention will now be described in further detail with reference to the accompanying drawings, so that those skilled in the art can implement it based on the description.

[0037] The term "comprising" and any variations thereof in the embodiments of this application are intended to cover non-exclusive inclusion. For example, a process, method, system, product, or device that includes a series of steps or units is not limited to the steps or units listed, but may optionally include steps or units not listed, or may optionally include other steps or units inherent to such process, method, product, or device.

[0038] In addition to the above, it should be emphasized that the reference to "embodiment" herein means that a specific feature, structure, or characteristic described in connection with an embodiment may be included in at least one embodiment of this application. The appearance of this phrase in various places in the specification does not necessarily refer to the same embodiment, nor is it a separate or alternative embodiment mutually exclusive with other embodiments. It will be explicitly and implicitly understood by those skilled in the art that the embodiments described herein can be combined with other embodiments.

[0039] Based on the foregoing analysis, the inventors of this application unexpectedly discovered through extensive research that neither arbutin nor edelweiss extract alone could have a positive effect on DNA damage in cells damaged by ultraviolet radiation. Only by combining α-arbutin and edelweiss in a specific ratio could a significant positive effect on DNA damage be achieved, demonstrating a clear synergistic effect.

[0040] Accordingly, the embodiments of this application provide the following technical solutions that can be used to repair damaged DNA.

[0041] In a first aspect, embodiments of this application propose the use of arbutin in synergistic inhibition of DNA damage by Edelweiss extract.

[0042] In a second aspect, embodiments of this application propose the use of Edelweiss extract for synergistic inhibition of DNA damage with arbutin.

[0043] In a third aspect, embodiments of this application propose the use of a composition containing arbutin and edelweiss extract for inhibiting DNA damage. For example, the composition containing arbutin and edelweiss extract can act as a DNA damage inhibitor to suppress DNA damage.

[0044] In a fourth aspect, embodiments of this application disclose the use of a composition containing arbutin and edelweiss extract in the preparation of a DNA damage inhibitor. For example, it can be prepared as a DNA damage inhibitor to suppress DNA damage.

[0045] In a fifth aspect, embodiments of this application propose the use of a composition containing arbutin and edelweiss extract in the preparation of cosmetics or pharmaceuticals for inhibiting DNA damage.

[0046] Furthermore, a fifth aspect embodiment provides the use of a composition containing arbutin and edelweiss extract as a DNA damage inhibitor in the preparation of cosmetics or pharmaceuticals for inhibiting DNA damage. In some embodiments, the DNA damage inhibitor may be as described in the sixth aspect embodiment below.

[0047] In some embodiments, the cosmetic is a face cream, sunscreen, moisturizing cream, face mask, serum, eye cream, makeup base, foundation, concealer, lotion, cleanser, toner, lotion, astringent, cosmetic lotion, or body lotion, etc.

[0048] In a sixth aspect, embodiments of this application propose a DNA damage inhibitor, comprising:

[0049] α-Arbutin;

[0050] Edelweiss extract;

[0051] The mass ratio of α-arbutin to Edelweiss extract is 0.5–70:1.

[0052] The sixth aspect, the DNA damage inhibitor, is a compound of α-arbutin and edelweiss extract in a specific ratio, which has a significant repair effect on DNA damage caused by UVB irradiation of keratinocytes.

[0053] Specifically, the DNA damage inhibitor can be used to inhibit DNA damage in keratinocytes.

[0054] More specifically, the DNA damage is damage caused by UVB irradiation.

[0055] In some embodiments, the mass ratio of α-arbutin to Edelweiss extract is 0.5 to 5:1, and more particularly 1 to 5:1.

[0056] In some embodiments, the mass ratio of α-arbutin to edelweiss extract is 2:1.

[0057] In a seventh aspect, embodiments of this application propose a skincare product with DNA damage inhibition function, comprising:

[0058] The DNA damage inhibitor described in the sixth aspect of the embodiments.

[0059] In some embodiments, the α-arbutin comprises 0.04% to 2% by mass of the total product; and the edelweiss extract comprises 0.01% to 5% by mass.

[0060] In some embodiments, the skincare product is a face cream, sunscreen, moisturizing cream, face mask, serum, eye cream, makeup base, foundation, concealer, lotion, cleanser, toner, lotion, astringent, cosmetic lotion, or body lotion, etc.

[0061] It should be noted that the Edelweiss extracts described in the above embodiments are prepared according to the preparation methods shown in steps S101-S103:

[0062] Step S101: Dry and pulverize the alpine edelweiss by blowing air, and pass it through a 40-60 mesh sieve to obtain alpine edelweiss pulverized material;

[0063] Step S102: Mix the pulverized edelweiss with an ethanol aqueous solution with a mass concentration of 60-80% to obtain a mixed solution, wherein the mass-to-volume ratio of the pulverized edelweiss to the ethanol aqueous solution in the mixed solution is 1:2.5-3.5 g / ml; it should be noted that each 1 g of pulverized edelweiss corresponds to 2.5-3.5 ml of ethanol aqueous solution;

[0064] Step S103: Reflux the mixed solution at 80-90°C for 40-60 minutes, filter it using a 500-800 mesh filter cloth, and concentrate the filtrate under reduced pressure to obtain Edelweiss extract.

[0065] <Use Verification of α-Arbutin and Edelweiss Extract>

[0066] Normally, after DNA damage occurs, phosphorylated histone H2AX (specifically γ-H2AX) aggregates at the damage site and guides repair proteins to repair the DNA. In other words, γ-H2AX usually has the following functions: recruiting and concentrating DNA repair proteins to restore the damaged DNA structure to its original state and enable it to perform the original functions of the damaged DNA again.

[0067] Since the content of γ-H2AX is positively correlated with the degree of DNA damage, it can be used as a biomarker to reflect the extent of DNA damage. Therefore, by measuring the expression level of γ-H2AX, the effectiveness of active ingredients in resisting DNA damage can be evaluated.

[0068] To investigate the inhibitory effect of the combination of α-arbutin and Edelweiss extract on DNA damage, this application combines the marker effect of γ-H2AX, uses keratinocytes as the research object, establishes a UVB-induced DNA damage model, and verifies the new use of α-arbutin and Edelweiss extract by setting up different control experiments.

[0069] Experimental materials

[0070] (1) Experimental cells: Human immortal keratinocyte line (HaCaT).

[0071] (2) Arbutin, also known as arbutin, has the chemical formula C. 12 H 16 O7.

[0072] (3) Edelweiss extract:

[0073] The Edelweiss extract was prepared according to the preparation methods shown in steps S201-S203:

[0074] Step S201: Dry and pulverize the edelweiss by blowing air, and pass it through a 50-mesh sieve to obtain edelweiss powder.

[0075] Step S202: Mix the pulverized edelweiss with a 70% ethanol aqueous solution to obtain a mixed solution, wherein the mass-volume ratio of the pulverized edelweiss to the ethanol aqueous solution in the mixed solution is 1:3 g / ml; it should be noted that each 1g of pulverized edelweiss corresponds to 3ml of ethanol aqueous solution;

[0076] Step S203: Reflux the mixed solution at 85°C for 50 minutes, filter it using a 600-mesh filter cloth, and concentrate the filtrate under reduced pressure to obtain Edelweiss extract.

[0077] (4) DMEM (dulbecco's modified eagle medium) basal medium, purchased from Thermo Fisher Scientific (China) Co., Ltd., Gibco biological medium, product code C11995500BT.

[0078] (5) Fetal bovine serum (FBS), purchased from Thermo Fisher Scientific (China) Co., Ltd., product code 10091148.

[0079] (6) Penicillin / streptomycin solution (10,000 U / mL), purchased from Thermo Fisher Scientific (China) Co., Ltd., Gibco brand penicillin / streptomycin, catalog number 25200114, wherein the penicillin / streptomycin solution includes penicillin and streptomycin, with concentrations of 10,000 U / mL respectively.

[0080] Cell culture

[0081] Take DMEM medium containing 10% FBS. This DMEM medium is composed of 89% DMEM basal medium, 10% fetal bovine serum, and 1% penicillin / streptomycin solution.

[0082] Pour the prepared DMEM medium (i.e., DMEM medium containing 10% FBS) into the T75 culture flask, and inoculate keratinocytes on the DMEM medium. Then, culture the inoculated keratinocytes under conditions of 5% carbon dioxide CO2 concentration and 37°C.

[0083] Cell passage culture: When keratinocytes reach 80-90% confluence, in a biosafety cabinet, add 2 mL of trypsin to the T75 culture flask to digest the adherent cells. After digestion, add 4 mL of DMEM medium (containing 10% FBS) to stop the trypsin digestion. Then, gently pipette the cells to detach them and collect them in a 15 mL centrifuge tube. Centrifuge at 1000 rpm for 3 min. Discard the old medium and resuspend the cells in fresh DMEM medium (containing 10% FBS). Passage or plate the cells as needed.

[0084] DNA damage resistance verification Experimental steps

[0085] Step (1): Take the keratinocytes from the above passaged culture and seed them into 6-well cell culture plates. Each well of the cell culture plate contains 1×10⁶ cells. 6 Cells were inoculated and placed in an incubator at 37°C and 5% carbon dioxide (CO2) concentration to allow the cells to adhere.

[0086] Step (II): When the cells reach 40-60% confluence, the cells on the cell culture plate are divided into different experimental groups such as negative control group, UVB irradiation control group and UVB irradiation drug administration group. Among them, the UVB irradiation drug administration group is further divided into arbutin group, alpine edelweiss extract group, composition 1 group, composition 2 group and composition 3 group.

[0087] Step (3): The corresponding drug treatments were added to the UVB irradiation treatment groups, namely the arbutin group, the edelweiss extract group, the composition 1 group, the composition 2 group, and the composition 3 group. The negative control group and the UVB irradiation control group were not treated. Then, the incubation was continued for 6 hours. The drug treatments for each group are shown in Table 1.

[0088] Table 1. Experimental Conditions

[0089]

[0090] Note 1: The 30 μg / ml arbutin culture medium solution in Table 1 is prepared from DMEM medium containing 10% FBS and a 30 mg / ml arbutin stock solution. The 30 mg / ml arbutin stock solution is prepared from α-arbutin and DMEM medium containing 10% FBS. Specifically, arbutin powder can be mixed into DMEM medium containing 10% FBS to form a 30 mg / ml arbutin stock solution.

[0091] Note 2: The 15 μg / ml Edelweiss extract culture medium solution in Table 1 is prepared by mixing DMEM medium containing 10% FBS and a 15 mg / ml Edelweiss extract stock solution. Each concentration of Edelweiss extract stock solution refers to a solution prepared by mixing DMEM medium containing 10% FBS with the corresponding Edelweiss extract. For example, a 15 mg / ml Edelweiss extract stock solution can be prepared by mixing Edelweiss extract powder into DMEM medium containing 10% FBS.

[0092] Note 3: It should be understood that the mass concentration of arbutin in a 30ug / ml arbutin culture medium solution is 30ug / ml; the mass concentration of arbutin in a 30mg / ml arbutin stock solution is 30mg / ml.

[0093] Note 4: It should also be understood that the concentration of edelweiss extract in the 15ug / ml edelweiss extract culture medium solution is 15ug / ml, and the concentration of edelweiss extract in the 15mg / ml edelweiss extract stock solution is 15mg / ml. Other concentrations of edelweiss extract stock solutions should be understood in a similar way.

[0094] Note 5: It should also be understood that the concentration of arbutin in the mixed culture medium solution of Composition 1 is 30 ug / ml, and the concentration of Edelweiss extract is 15 ug / ml, that is, the mass ratio of arbutin to Edelweiss extract is 2:1; the concentration of arbutin in the mixed culture medium solution of Composition 2 is 30 ug / ml, and the concentration of Edelweiss extract is 30 ug / ml, that is, the mass ratio of arbutin to Edelweiss extract is 1:1; the concentration of arbutin in the mixed culture medium solution of Composition 3 is 30 ug / ml, and the concentration of Edelweiss extract is 5 ug / ml, that is, the mass ratio of arbutin to Edelweiss extract is 6:1.

[0095] Step (IV): After 24 hours of incubation, cells in the UVB irradiation control group and the UVB irradiation drug group were treated with UVB light at an energy of 25 mJ / cm², and then covered with DMEM medium containing 10% FBS for another 6 hours. After 6 hours, dead cells were washed away with phosphate-buffered saline (PBS) to obtain the corresponding test cells for each UVB irradiation group. The negative control group was not irradiated, and the corresponding test cells were obtained directly. The UVB irradiation details for each group can be further referred to the experimental conditions shown in Table 1.

[0096] Step (5): Western blotting (WB) was used to verify the anti-DNA damage properties of each group of cells. Cell images of each group of cells were acquired, and then image processing was performed using Photoshop CS5. The γ-H2AX grayscale results of the cells were analyzed using ImageJ software to evaluate the strength of the anti-DNA damage properties of each group of cells.

[0097] Experimental results :

[0098] The γ-H2AX grayscale results for each group of cells to be tested can be found in [reference needed]. Figure 1 .about Figure 1 It should be noted that: the molecular weight of γ-H2AX in the figure is 16 kDa; the molecular weight of β-actin is 42 kDa. It serves as an internal reference to calibrate the amount of protein loaded and ensure the accuracy of experimental results. In this embodiment, it is used as a blank control to detect whether the protein transfer is complete and whether the luminescence system is normal during WB.

[0099] in addition, Figure 1 The intensity of the bands corresponding to β-actin and γ-H2AX in each group represents the level of protein expression.

[0100] Figure 1 The "+" indicates that the experimental group pointed to has the corresponding experimental conditions, and the "-" indicates that the experimental group pointed to lacks the corresponding experimental conditions.

[0101] The term "KDa" refers to kilodaltons.

[0102] Therefore, it is understandable that Figure 1 The relative protein content levels of γ-H2AX in each group of cells under test were expressed. For details, please refer to the intensity of the corresponding γ-H2AX bands, where intensity represents the level of protein expression. More specifically, in Figure 1 In the middle, the first band from the left shows the relative protein expression level of γ-H2AX in the negative control group, the second band from the left shows the relative protein expression level of γ-H2AX in the UVB irradiation control group, and the fifth, fourth, third, second and first bands from the right show the relative protein expression levels of γ-H2AX in the arbutin group, the edelweiss extract group, the composition 2 group, the composition 3 group and the composition 1 group, respectively. Figure 1 The relative protein content of γ-H2AX in each group of cells to be tested can be found in Table 2.

[0103] Table 2

[0104] Group Mean ± Standard Deviation negative control group 1.00±0.00 UVB irradiation control group 1.69±0.09 Arbutin group 2.60±0.54 Edelweiss extract group 1.74±0.19 Group 1 of the composition 1.05±0.03 Composition 2 groups 1.45±0.04 Composition 3 groups 1.85±0.46

[0105] In addition, the significance of each group of γ-H2AX grayscale results was calculated, and then statistical graphs of each group of γ-H2AX grayscale results were plotted using GraphPad Prism software. These graphs can be referenced. Figure 2 .exist Figure 2 In the diagram, "**" indicates the significance of the UVB irradiation control group relative to the negative control group, and "*" indicates the significance of each UVB irradiation drug administration group relative to the UVB irradiation control group.

[0106] Analysis of experimental results:

[0107] according to Figure 1-2 As can be seen from the results in Table 2:

[0108] Combination Figure 2 Comparing the experimental results of the negative control group and the UVB irradiation control group, it can be determined that ultraviolet radiation irradiation of keratinocytes induces DNA damage by causing breaks in the DNA of keratinocytes. After DNA damage, γ-H2AX is rapidly formed inside the cell.

[0109] Continue to combine Figure 2 As shown, it can be found that: 30 μg / ml arbutin did not show a positive regulatory effect on DNA damage (see the results of the arbutin group); 15 μg / ml Edelweiss extract also did not show a positive regulatory effect on DNA damage (see the results of the Edelweiss extract group); however, the combination of 30 μg / ml arbutin and 30 μg / ml Edelweiss extract (see the results of combination group 2) and the combination of 30 μg / ml arbutin and 15 μg / ml Edelweiss extract (see the results of combination group 1) showed a significant inhibitory effect on γ-H2AX.

[0110] In summary, it can be determined that in the composition containing Edelweiss extract and arbutin, when the mass ratio of Edelweiss extract to arbutin increases from 1:6 to 1:2, the relative protein content of γ-H2AX shows a decreasing trend, and the repair effect on damaged DNA of keratinocytes under ultraviolet irradiation increases; while when the mass ratio continues to increase from 1:2 to 1:1, the relative protein content of γ-H2AX no longer shows a decreasing trend.

[0111] Based on the above results, it can be determined that in the composition containing Edelweiss extract and arbutin, when the mass ratio of arbutin to Edelweiss extract is 1 to 5:1, a good synergistic effect can be achieved, effectively inhibiting DNA damage caused by UVB irradiation; and when the mass ratio is 2:1, the repair effect on damaged DNA is the best.

[0112] It is easy to understand that the DNA damage inhibitor proposed in the sixth aspect embodiment is a composition containing edelweiss extract and arbutin. Since it includes α-arbutin and edelweiss extract, and the mass ratio of α-arbutin to edelweiss extract is 1 to 5:1, it also has a significant repair effect on the damaged DNA of keratinocytes exposed to ultraviolet radiation.

[0113] Furthermore, it should be understood that, in order to facilitate cell absorption of arbutin and edelweiss extract, in some embodiments, arbutin and edelweiss extract can be first dissolved in a solvent to form a solution before being used for cellular DNA repair. Therefore, it can be determined that, in at least one embodiment, the DNA damage inhibitor also includes a solvent, which can enhance the repair effect. Further, the solvent is water.

[0114] Application Example 1

[0115] Application Example 1 provides an essence water that includes:

[0116] Phase A consists of 3g glycerol, 0.1g carbomer, and 90.3g water;

[0117] Phase B, comprising 0.1g of triethanolamine;

[0118] Phase C includes 2g of α-arbutin and 0.5g of Edelweiss extract;

[0119] Phase D consists of 0.5g of p-hydroxyacetophenone, 0.5g of hexanediol, and 3g of butylene glycol.

[0120] The preparation steps for the essence water in Application Example 1 are as follows:

[0121] Swell the A phase raw material evenly and homogenize it until it is completely dispersed;

[0122] After complete dispersion, add phase B and stir until clear and transparent;

[0123] After clarifying and clarifying the mixture, add phase C and stir until homogeneous to obtain a mixture of phases A, B, and C.

[0124] Heat phase D at 65°C until it becomes clear and transparent, then cool it to room temperature. Add the solution to the mixture and stir until homogeneous to obtain the essence water.

[0125] Application Example 2

[0126] Application Example 2 provides an essence lotion comprising:

[0127] Phase A: 3g glycerin, 0.1g carbomer, 0.1g xanthan gum, and 84.6g water;

[0128] Phase B: 5g of isononyl isononanoate and 0.6g of PEG-100 stearic acid;

[0129] Phase C: Triethanolamine 0.15g;

[0130] Phase D: α-Arbutin 2g and Edelweiss Extract 0.5g;

[0131] Phase E: 0.5g p-hydroxyacetophenone, 0.5g hexanediol, and 3g butylene glycol.

[0132] The preparation steps of the essence emulsion in Application Example 2 are as follows:

[0133] Swell the A phase raw material evenly and homogenize it until it is completely dispersed;

[0134] Heat phase A and phase B to 80°C respectively, then add phase A to phase B and homogenize for 2-3 minutes at 80°C.

[0135] After homogenization, continue to add phase C and stir until homogeneous. Then, cool the mixture to 40°C and add phase D and stir until homogeneous to obtain the mixture.

[0136] Phase E was heated to 65°C until it became clear and transparent, then cooled to room temperature. It was then added to the mixture and stirred until homogeneous to obtain the essence emulsion.

[0137] Both the essence water of Application Example 1 and the essence lotion of Application Example 2 showed significant anti-DNA damage effects. In other words, the skincare products with DNA damage inhibition function proposed in this application can achieve better skincare results through their anti-DNA damage effect.

[0138] Although embodiments of the present invention have been disclosed above, they are not limited to the applications listed in the specification and embodiments. They can be applied to various fields suitable for the present invention. For those skilled in the art, other modifications can be easily made. Therefore, without departing from the general concept defined by the claims and their equivalents, the present invention is not limited to the specific details and illustrations shown and described herein.

Claims

1. The use of a composition containing arbutin and edelweiss extract in the preparation of DNA damage inhibitors; wherein, The DNA damage inhibitor is used to repair DNA damage caused by UVB irradiation, and the mass ratio of α-arbutin to the edelweiss extract is 1~5:

1.

2. The use according to claim 1, wherein, The edelweiss extract was prepared according to the following method: The alpine edelweiss was dried and pulverized by blowing air, and then passed through a 40-60 mesh sieve to obtain alpine edelweiss powder. The pulverized alpine edelweiss was mixed with an ethanol aqueous solution with a mass concentration of 60-80%, wherein the mass-to-volume ratio of the pulverized alpine edelweiss to the ethanol aqueous solution was 1:2.5-3.5 g / ml. Extract by reflux at 80-90℃ for 40-60 minutes, filter using a 500-800 mesh filter cloth, and concentrate the filtrate under reduced pressure to obtain Edelweiss extract.

3. The use according to claim 1, wherein, The mass ratio of α-arbutin to the edelweiss extract is 1~2:

1.

4. The use of a composition containing arbutin and edelweiss extract in the preparation of cosmetics or pharmaceuticals for inhibiting DNA damage induced by UVB irradiation; wherein, The mass ratio of α-arbutin to the edelweiss extract is 1~5:

1.

5. The use according to claim 4, wherein, The edelweiss extract was prepared according to the following method: The alpine edelweiss was dried and pulverized by blowing air, and then passed through a 40-60 mesh sieve to obtain alpine edelweiss powder. The pulverized alpine edelweiss was mixed with an ethanol aqueous solution with a mass concentration of 60-80%, wherein the mass-to-volume ratio of the pulverized alpine edelweiss to the ethanol aqueous solution was 1:2.5-3.5 g / ml. Extract by reflux at 80-90℃ for 40-60 minutes, filter using a 500-800 mesh filter cloth, and concentrate the filtrate under reduced pressure to obtain Edelweiss extract.

6. The use according to claim 1, wherein, The mass ratio of α-arbutin to the edelweiss extract is 1~2:

1.

7. A DNA damage inhibitor, characterized in that, include: α-Arbutin; and Edelweiss extract; The mass ratio of α-arbutin to the edelweiss extract is 1~5:1; The edelweiss extract was prepared according to the following method: The alpine edelweiss was dried and pulverized by blowing air, and then passed through a 40-60 mesh sieve to obtain alpine edelweiss powder. The pulverized alpine edelweiss was mixed with an ethanol aqueous solution with a mass concentration of 60-80%, wherein the mass-to-volume ratio of the pulverized alpine edelweiss to the ethanol aqueous solution was 1:2.5-3.5 g / ml. Extract by reflux at 80-90℃ for 40-60 minutes, filter using a 500-800 mesh filter cloth, and concentrate the filtrate under reduced pressure to obtain Edelweiss extract.

8. The DNA damage inhibitor according to claim 7, characterized in that, The mass ratio of α-arbutin to the edelweiss extract is 1~2:

1.

9. A skincare product with DNA damage inhibition function, characterized in that, include: The DNA damage inhibitor according to any one of claims 7-8.

10. The skincare product according to claim 9, characterized in that, The skincare product is either a face cream or a lotion.

11. The skincare product according to claim 9, characterized in that, The skincare products mentioned are any one of the following: sunscreen, face cream, face mask, serum, eye cream, makeup base, foundation, concealer, facial cleanser, toner, lotion, astringent, facial lotion, and body lotion.

Images